BR112015020716A2 - processo para a preparação de (2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)-5,6-diidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)-1h-pirazol-1-il)-2-metilpropanamida (i) e composto - Google Patents
processo para a preparação de (2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)-5,6-diidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)-1h-pirazol-1-il)-2-metilpropanamida (i) e compostoInfo
- Publication number
- BR112015020716A2 BR112015020716A2 BR112015020716A BR112015020716A BR112015020716A2 BR 112015020716 A2 BR112015020716 A2 BR 112015020716A2 BR 112015020716 A BR112015020716 A BR 112015020716A BR 112015020716 A BR112015020716 A BR 112015020716A BR 112015020716 A2 BR112015020716 A2 BR 112015020716A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- oxazepin
- methylpropanamide
- dihydrobenzo
- imidazo
- Prior art date
Links
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229950001269 taselisib Drugs 0.000 abstract 2
- 239000012828 PI3K inhibitor Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779619P | 2013-03-13 | 2013-03-13 | |
| PCT/EP2014/054786 WO2014140073A1 (en) | 2013-03-13 | 2014-03-12 | Process for making benzoxazepin compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015020716A2 true BR112015020716A2 (pt) | 2017-07-18 |
Family
ID=50241450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015020716A BR112015020716A2 (pt) | 2013-03-13 | 2014-03-12 | processo para a preparação de (2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)-5,6-diidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)-1h-pirazol-1-il)-2-metilpropanamida (i) e composto |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9303043B2 (enExample) |
| EP (3) | EP2970329A1 (enExample) |
| JP (6) | JP6363120B2 (enExample) |
| KR (3) | KR101821468B1 (enExample) |
| CN (2) | CN105377856B (enExample) |
| AR (1) | AR095365A1 (enExample) |
| AU (3) | AU2014230812B2 (enExample) |
| BR (1) | BR112015020716A2 (enExample) |
| CA (6) | CA2948765A1 (enExample) |
| IL (1) | IL240793A0 (enExample) |
| MX (1) | MX2015011438A (enExample) |
| NZ (1) | NZ711192A (enExample) |
| RU (2) | RU2649976C2 (enExample) |
| SG (2) | SG10201706760YA (enExample) |
| WO (1) | WO2014140073A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201604903VA (en) * | 2013-12-16 | 2016-07-28 | Hoffmann La Roche | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof |
| CN107995911B (zh) | 2015-07-02 | 2020-08-04 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 |
| EP4585597A1 (en) | 2015-07-02 | 2025-07-16 | F. Hoffmann-La Roche AG | Benzoxazepin oxazolidinone compounds and methods of use |
| CN105906635A (zh) * | 2016-06-08 | 2016-08-31 | 上海大学 | 全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法 |
| WO2018021508A1 (ja) * | 2016-07-29 | 2018-02-01 | 日本たばこ産業株式会社 | ピラゾール－アミド化合物の製造方法 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| SG10201913961PA (en) | 2016-12-15 | 2020-03-30 | Hoffmann La Roche | Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide |
| CN108752237A (zh) * | 2018-07-05 | 2018-11-06 | 四川青木制药有限公司 | 一种对氨基苯甲脒盐酸盐的新制备方法 |
| CN113195000A (zh) | 2018-12-21 | 2021-07-30 | 第一三共株式会社 | 抗体-药物缀合物和激酶抑制剂的组合 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
| US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| JP4677100B2 (ja) * | 1998-10-23 | 2011-04-27 | ダウ・アグロサイエンス・エル・エル・シー | ３−（置換フェニル）−５−（置換シクロプロピル）−１，２，４−トリアゾール化合物 |
| BR0211073A (pt) | 2001-07-12 | 2004-12-14 | Avecia Ltd | Sistema de catalisador, e, processos para a preparação de um catalisador microencapsulado, de bifenilas opcionalmente substituìdas, de alcenos opcionalmente substituìdos, de um produto hidrogenado e de dióis |
| DE60208815T2 (de) * | 2001-10-12 | 2006-07-20 | Bayer Pharmaceuticals Corp., West Haven | Phenyl substituierte 5-gliedrige stickstoff enthaltende heterocyclen zur behandlung von fettleibigkeit |
| CA2627839C (en) | 2005-11-02 | 2014-08-19 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| KR20090071612A (ko) * | 2006-10-23 | 2009-07-01 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 단백질 키나제 조정제로서의 바이시클릭 트리아졸 |
| PL2081937T3 (pl) | 2006-10-23 | 2013-01-31 | Sgx Pharmaceuticals Inc | Triazolopirydazynowe modulatory kinaz białkowych |
| JP2010516680A (ja) * | 2007-01-19 | 2010-05-20 | エックスカバリー，インコーポレイテッド | キナーゼ阻害薬化合物 |
| US8354528B2 (en) * | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| ES2556353T3 (es) * | 2008-02-21 | 2016-01-15 | Merck Sharp & Dohme Corp. | Compuestos que son inhibidores de las ERK |
| PL2276767T3 (pl) | 2008-03-31 | 2014-09-30 | Genentech Inc | Związki benzopiranowe i benzoksepinowe będące inhibitorami pi3k oraz metody ich stosowania |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| WO2011036280A1 (en) * | 2009-09-28 | 2011-03-31 | F. Hoffmann-La Roche Ag | Benzoxazepin pi3k inhibitor compounds and methods of use |
| RU2557658C2 (ru) * | 2009-09-28 | 2015-07-27 | Ф.Хоффманн-Ля Рош Аг | Бензоксепиновые ингибиторы pi3 и способы применения |
| AU2010313469A1 (en) * | 2009-10-29 | 2012-06-07 | Merck Sharp & Dohme Corp. | Bridged Bicyclic Piperidine Derivatives and methods of use thereof |
| CN102558167A (zh) * | 2010-12-29 | 2012-07-11 | 中国医学科学院药物研究所 | Gk和ppar双重激动活性的噻唑烷二酮衍生物 |
| CA2825966A1 (en) | 2011-03-21 | 2012-09-27 | F. Hoffmann-La Roche Ag | Benzoxazepin compounds selective for pi3k p110 delta and methods of use |
| NO3175985T3 (enExample) * | 2011-07-01 | 2018-04-28 | ||
| SG10201706196XA (en) | 2012-06-08 | 2017-08-30 | Hoffmann La Roche | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
-
2014
- 2014-03-12 AR ARP140100904A patent/AR095365A1/es unknown
- 2014-03-12 SG SG10201706760YA patent/SG10201706760YA/en unknown
- 2014-03-12 JP JP2015562108A patent/JP6363120B2/ja active Active
- 2014-03-12 CA CA2948765A patent/CA2948765A1/en not_active Abandoned
- 2014-03-12 CA CA2897618A patent/CA2897618A1/en not_active Abandoned
- 2014-03-12 CA CA2948763A patent/CA2948763C/en not_active Expired - Fee Related
- 2014-03-12 MX MX2015011438A patent/MX2015011438A/es unknown
- 2014-03-12 AU AU2014230812A patent/AU2014230812B2/en not_active Ceased
- 2014-03-12 CN CN201480015055.8A patent/CN105377856B/zh active Active
- 2014-03-12 NZ NZ711192A patent/NZ711192A/en not_active IP Right Cessation
- 2014-03-12 KR KR1020157024484A patent/KR101821468B1/ko not_active Expired - Fee Related
- 2014-03-12 EP EP14709314.0A patent/EP2970329A1/en not_active Withdrawn
- 2014-03-12 CA CA3005103A patent/CA3005103A1/en not_active Abandoned
- 2014-03-12 SG SG11201507394RA patent/SG11201507394RA/en unknown
- 2014-03-12 RU RU2015138488A patent/RU2649976C2/ru not_active IP Right Cessation
- 2014-03-12 CA CA3005112A patent/CA3005112A1/en not_active Abandoned
- 2014-03-12 BR BR112015020716A patent/BR112015020716A2/pt not_active Application Discontinuation
- 2014-03-12 US US14/205,634 patent/US9303043B2/en active Active
- 2014-03-12 CN CN201810489045.8A patent/CN108929333A/zh active Pending
- 2014-03-12 EP EP18173513.5A patent/EP3404032B1/en active Active
- 2014-03-12 KR KR1020187016976A patent/KR20180070715A/ko not_active Withdrawn
- 2014-03-12 CA CA3005118A patent/CA3005118A1/en not_active Abandoned
- 2014-03-12 KR KR1020177016062A patent/KR101871133B1/ko not_active Expired - Fee Related
- 2014-03-12 RU RU2018109979A patent/RU2018109979A/ru not_active Application Discontinuation
- 2014-03-12 WO PCT/EP2014/054786 patent/WO2014140073A1/en not_active Ceased
- 2014-03-12 EP EP20204345.1A patent/EP3845540A1/en active Pending
-
2015
- 2015-08-24 IL IL240793A patent/IL240793A0/en unknown
-
2016
- 2016-06-28 AU AU2016204432A patent/AU2016204432B2/en not_active Ceased
-
2017
- 2017-07-10 JP JP2017135083A patent/JP6442005B2/ja active Active
-
2018
- 2018-02-27 AU AU2018201393A patent/AU2018201393A1/en not_active Abandoned
- 2018-03-12 JP JP2018044050A patent/JP2018150298A/ja active Pending
- 2018-08-16 JP JP2018153231A patent/JP6663459B2/ja active Active
- 2018-11-22 JP JP2018219226A patent/JP2019089762A/ja active Pending
-
2020
- 2020-02-28 JP JP2020032846A patent/JP2020114814A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015020716A2 (pt) | processo para a preparação de (2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)-5,6-diidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)-1h-pirazol-1-il)-2-metilpropanamida (i) e composto | |
| BR112016014018B8 (pt) | Processo para a preparação dos compostos de cetona (ia), e processo para a preparação dos compostos de triazol de fórmula (ic) | |
| CR20130470A (es) | INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [2,3-d]PIRIMIDINA TROMPOMIOSINA | |
| CU24354B1 (es) | Procedimiento de obtención de derivados de tetrafluoropropilmorfolina | |
| BR112014005226A2 (pt) | derivados de benzonitrila como inibidores de cinase | |
| MX2015013042A (es) | Compuestos organicos. | |
| CU24263B1 (es) | Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer | |
| SMT201600393B (it) | Metodo per la fabbricazione di materiali cementizi supplementari (scm) | |
| BR112015005694A2 (pt) | pró-fármacos de inibidor amino-quinazoliníco de quinase | |
| BR112017028322A2 (pt) | compostos, processo para a produção de compostos i, para a produção de compostos ii dos compostos iii e para a produção de compostos iii, compostos intermediários v e utilização dos compostos i | |
| GT201300078A (es) | Proceso para la preparacion de inhibidores de pan-cdk de la formula ( i ), e intermediarios de la preparacion | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| BR112014010997A2 (pt) | processo para o preparo de ß-glicosídeos de c-arila | |
| AR098394A1 (es) | Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2) | |
| UA116801C2 (uk) | ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2 | |
| UY35746A (es) | Derivados de fenilalanina sustituidos | |
| BRPI1005793A2 (pt) | processo para preparar os 2-aminobifenis substituídos de fórmula i, composto de fórmula ia ou ib e processo para o preparo de pirazolecarboxamidas de fórmula iv | |
| BR112015014822A2 (pt) | compostos de fórmula i, composição, utilização de um composto, método para o combate dos fungos nocivos e semente revestida | |
| MX369323B (es) | Pildoras de desfluidización solubles en acido. | |
| EP2702044A4 (en) | PROCESS FOR RILPIVIRIN | |
| CR20150006A (es) | Metodo para preparar triazolopiridinas sustituidas | |
| BR112015015798A2 (pt) | método para a preparação de um composto | |
| BR112016009665A8 (pt) | polimorfos, composição farmacêutica, processos para a preparação de um polimorfo e usos dos polimorfos | |
| MX2020009462A (es) | Procesos para la preparación de compuestos de pirimidinilciclopentano. | |
| BR112016016397A2 (pt) | método para preparar 1-alquil-3-difluorometil-5-fluoro-1h-pirazol-4-carbaldeídos e 1-alquil-3-difluorometil-5-fluoro-1h-pirazol-4-carboxilatos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |